AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Byline: Jeff Swiatek
Apr. 18--An osteoporosis drug made by Eli Lilly and Co. also prevents breast cancer in older, high-risk women just as well as today's standby tamoxifen -- but with fewer side effects, the National Cancer Institute announced Monday.
The five-year government study showed that Evista reduced by 50 percent the risk of developing invasive breast cancer among women who were at risk of getting the disease. That was comparable to the other drug studied in the trial, Nolvadex, which is a currently approved treatment for breast cancer.
The finding, coming out of one of the largest breast cancer prevention clinical trials ever conducted, …